Nippon Shinyaku Exercises US Option for AB2 Bio’s Tadekinig Alfa

Shots: Nippon has exercised its exclusive US commercialization option for tadekinig alfa in Primary Monogenic IL-18-Driven Hyperinflammatory Syndrome with NLRC4 & XIAP mutations, with AB2 Bio retaining US rights to all other indications & all rights outside the US AB2 Bio received a $6M option fee in 2025 & will now receive a $30M option…

ByRidhi RastogiJuly 30, 2026

NEWS

J&J Partners with Sail Biomedicines to Advance In Vivo CAR-T Therapies

Shots: J&J has entered strategic agreements & collaboration with Sail to advance its lead immune-mediated disease program & in vivo CAR-T platform, with the potential to expand the platform across additional therapeutic targets As per the deal, Sail will receive initial payments of $785M, incl. a $465M equity investment, with additional contingent payments of ~$140M…

ByRidhi RastogiJuly 30, 2026

NEWS

AbCellera and Vertex Pharmaceuticals Team Up on T-Cell Engagers

Shots: AbCellera has entered into a collaboration with Vertex to research, develop, manufacture, & commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases & other conditions As per the deal, AbCellera will use its TCE platform for discovery & early development, while Vertex will fund all R&D costs and retain rights to develop & commercialize resulting…

ByRidhi RastogiJuly 29, 2026

NEWS

CORE Biomedicine Licenses Preclinical Oncology Portfolio from Eisai

Shots: CORE Biomedicine has entered into a licensing agreement with Eisai, securing exclusive global rights to develop & commercialize multiple preclinical oncology programs As per the deal, CORE will obtain exclusive, global rights to certain preclinical oncology programs spanning distinct targets & biological pathways, providing CORE with a broad pipeline to develop next-generation precision medicines…

ByRidhi RastogiJuly 29, 2026

NEWS

Royalty Pharma Inks ~$425M Deal with Neurimmune to Acquire Royalty Interest in AstraZeneca’s Cliramitug

Shots: Royalty Pharma will pay Neurimmune up to $425M, incl. $125M upfront, in exchange for a 3% to 4% royalty on worldwide net sales of AstraZeneca’s cliramitug Royalty Pharma will pay Neurimmune an additional $125M in cash in Q1’27, with the remaining $175M contingent on the achievement of specified clinical & regulatory milestones Cliramitug is…

ByRidhi RastogiJuly 23, 2026

NEWS

Jupiter Neurosciences Inks ~$100M Deal with PharmAla Biotech for Exclusive US Rights to ALA-002

Shots: Jupiter Neurosciences has entered into a definitive license agreement with PharmAla Biotech for perpetual exclusive US rights to ALA-002, a FDA NCE-designated, non-racemic MDMA formulation Jupiter Neurosciences will receive perpetual exclusive US rights to ALA-002 for $3.3M upfront ($1.5M cash + $1.8M JUNS common stock), with the deal valued at up to $100M, incl.…

ByRidhi RastogiJuly 22, 2026

NEWS

Akari and Whitehawk Partner to Evaluate Dual-Payload ADC Approach

Shots: Akari has entered into a strategic research collaboration with Whitehawk to evaluate Akari’s PH1 spliceosome-modulating payload tech in combination with Whitehawk’s TOP1i ADC platform As per the deal, Akari will lead the design, execution, & evaluation of the research program, which will incl. multiple preclinical workstreams assessing dual-payload compatibility & potential synergies Collaboration begins…

ByRidhi RastogiJuly 21, 2026

NEWS

Incyte Partners with Halozyme to Develop Subcutaneous INCA033989

Shots: Incyte has entered into a global collaboration & license agreement with Halozyme to evaluate additional SC formulations of INCA033989 for pts with mutCALR-expressing myeloproliferative neoplasms, using Halozyme's Enhanze tech As per the deal, Halozyme will receive an upfront payment, as well as milestone payments, plus royalties, with Incyte having an option to nominate up…

ByRidhi RastogiJuly 21, 2026

NEWS

Aqemia Expands Sanofi Collaboration With New Target Nomination

Shots: Aqemia has expanded its multi-year research collaboration with Sanofi, marked by the nomination of a new therapeutic target & an additional payment The collaboration, initially announced in Dec 2023, makes Aqemia eligible to receive up to a total of $140M in upfront & milestone payments across programs Aqemia uses its physics-based generative AI platform,…

ByRidhi RastogiJuly 17, 2026

NEWS

Mission Therapeutics Inks a ~$292M Deal with Dimerix for MTX652

Shots: Mission Therapeutics has reported the divestment of its P-II-ready asset MTX652, to Dimerix for initial development in Acute Kidney Injury (AKI) As per the deal, Mission will receive ~$292M in upfront, development & commercial milestones, plus up to double-digit tiered royalties on global net sales The divestment aligns with Mission’s strategy to maximize its…

ByRidhi RastogiJuly 17, 2026

Nippon Shinyaku Exercises US Option for AB2 Bio’s Tadekinig Alfa

J&J Partners with Sail Biomedicines to Advance In Vivo CAR-T Therapies

AbCellera and Vertex Pharmaceuticals Team Up on T-Cell Engagers

CORE Biomedicine Licenses Preclinical Oncology Portfolio from Eisai

Royalty Pharma Inks ~$425M Deal with Neurimmune to Acquire Royalty Interest in AstraZeneca’s Cliramitug

Jupiter Neurosciences Inks ~$100M Deal with PharmAla Biotech for Exclusive US Rights to ALA-002

Akari and Whitehawk Partner to Evaluate Dual-Payload ADC Approach

Incyte Partners with Halozyme to Develop Subcutaneous INCA033989

Aqemia Expands Sanofi Collaboration With New Target Nomination

Mission Therapeutics Inks a ~$292M Deal with Dimerix for MTX652

Contact US

FOLLOW US